BPC-157 vs Humanin

BPC-157 and Humanin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157, a synthetic peptide composed of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight ~1419.5 g/mol), is derived from a protein found in human gastric juice. Research indicates that BPC-157 exhibits significant regenerative and cytoprotective properties, with extensive animal studies highlighting its efficacy in healing various tissues, including tendons, ligaments, muscles, bones, nerves, and the gastrointestinal tract. Despite these promising findings, human clinical data remains sparse; as of 2025, only three pilot studies have explored its effects in humans, focusing on knee pain (n=16), interstitial cystitis (n=12), and intravenous safety (n=2). The FDA categorizes BPC-157 as Category 2, which restricts its compounding, and the World Anti-Doping Agency (WADA) prohibits its use in competitive sports, indicating significant regulatory concerns surrounding its application.

Humanin is a mitochondria-derived peptide (MDP) consisting of 21-24 amino acids, encoded by the MT-RNR2 gene located in mitochondrial DNA. Initially identified in 2001 for its neuroprotective effects against Alzheimer's disease-related toxicity, subsequent research has unveiled its broader cytoprotective, anti-inflammatory, anti-apoptotic, and metabolic roles. Notably, studies suggest that circulating levels of Humanin decline with age, and its presence has been correlated with longevity in centenarian populations. While the peptide shows promise in various therapeutic contexts, including neuroprotection and metabolic health, comprehensive human clinical data remains limited, necessitating further investigation to fully understand its potential benefits and mechanisms of action.

BPC-157 and Humanin, while both classified as research peptides, target distinct areas of interest within the scientific community. BPC-157 is primarily investigated for its applications in injury recovery and gut health, showcasing its regenerative capabilities in various tissues. In contrast, Humanin is explored in the realms of anti-aging and cognitive enhancement, with a focus on its neuroprotective properties and potential metabolic benefits. The divergence in their research applications highlights the unique roles each peptide may play in advancing therapeutic strategies, emphasizing the importance of selecting the appropriate peptide based on specific research objectives.

The safety profiles of BPC-157 and Humanin present important considerations for researchers. For BPC-157, there are no completed randomized controlled trials assessing safety in humans. However, preclinical studies across various animal models have indicated no toxic or lethal dose thresholds at administered ranges from 6 mcg/kg to 20 mg/kg, with no observed teratogenic, genotoxic, or anaphylactic effects during necropsy and histopathology evaluations. The FDA previously classified BPC-157 as Category 2 due to significant safety concerns, but this classification was removed on April 15, 2026, with a review by the PCAC pending in July 2026 to determine compounding eligibility. In contrast, Humanin, being an endogenous peptide naturally present in human circulation, lacks formal human safety data but has not reported adverse effects in animal studies at tested doses, suggesting a potentially favorable safety profile.